What is RISA?
Founded in 2024, RISA Labs operates at the intersection of artificial intelligence and oncology. The company provides a sophisticated platform designed to automate the prior authorization process, a notorious bottleneck in the U.S. healthcare system. By utilizing a combination of generative AI, robotic process automation, and a proprietary rules engine, RISA Labs effectively bridges the gap between clinical necessity and administrative compliance. Their technology is engineered to integrate seamlessly with major EHR platforms, allowing healthcare providers to reduce treatment delays and improve operational efficiency. By focusing on the high-stakes domain of oncology, RISA Labs addresses a critical market need for evidence-based care optimization and administrative streamlining.
How much funding has RISA raised?
RISA has raised a total of $14.6M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$11.1M
Angel/Seed (2025): $3.5M with participation from Oncology Ventures, Binny Bansal, and General Catalyst
Series A (2026): $11.1M led by Optum Ventures
Key Investors in RISA
Oncology Ventures
Oncology Ventures is dedicated to investing in healthcare data companies that address significant challenges in cancer care, focusing on early detection, patient navigation, and AI-powered treatment optimization.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages, leveraging deep operational expertise to accelerate growth.
Optum Ventures
Optum Ventures was created to make health care better for everyone, investing in early-stage companies that are poised to disrupt the status quo.
What's next for RISA?
With the successful closure of this major enterprise-level funding, RISA Labs is poised to enter a phase of rapid scaling and product expansion. The strategic focus will likely shift toward broadening the platform's capabilities to handle more complex authorization workflows and expanding its footprint across major hospital networks. As the company matures, the integration of its AI-driven multi-agent systems will be pivotal in demonstrating measurable improvements in patient outcomes and provider productivity. The backing from prominent healthcare-focused investors suggests a long-term commitment to building a sustainable, high-impact enterprise that can navigate the regulatory and operational complexities of the oncology market. Future growth will likely center on enhancing the platform's interoperability and proving its value proposition to large-scale health systems seeking to mitigate the rising costs of administrative overhead.
See full RISA company page
